Neurovax
From Wikipedia, the free encyclopedia
Neurovax is a vaccine designed to treat patients with Multiple Sclerosis (M.S.). Developed by Immune Response BioPharma, Inc. it is currently in phase II clinical trials. Neurovax is designed to stimulate FOXP3+ regulatory T-cells that can then suppress the autoreactive T-cells in some patients.
All work with Neurovax is now being developed by Immune Response BioPharma, Inc. and has licensed TCR FOXP3+ Technology from OHSU in December 2011.
[edit] External Links
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
